REDX Redx Pharma Plc

TIDMREDX

RNS Number : 8180Q

Redx Pharma plc

01 November 2021

REDX PHARMA PLC

("Redx" or "the Company")

Redx Announces the Appointment of Dr Jane Griffiths, an Accomplished Pharma Industry Executive and Board Director, as Non-Executive Chair

Alderley Park, UK, 1 November 2021 - Redx Pharma (AIM:REDX), the drug discovery and development company focused on oncology and fibrosis, is pleased to announce the appointment of Dr Jane Griffiths as Non-Executive Chair, effective from 1 December 2021. Jane brings significant experience and understanding of managing global strategy across the pharmaceutical sector, together with a strong interest in sustainability and diversity.

Jane has enjoyed a long and successful career in the pharmaceutical sector with Johnson & Johnson. During her tenure there she held executive roles in clinical research, international and strategic marketing, product management and operational management. In her last role before retiring in December 2019, Jane was Global Head of Actelion, where she led the integration of the Swiss biotech business following its acquisition by Johnson & Johnson. Prior to that Jane had been Company Group Chair of Janssen EMEA, the group's research based pharmaceutical arm. During her time with Johnson & Johnson, Jane led its Corporate Citizen Trust in EMEA and sponsored its Women's Leadership Initiative. Jane was also sponsor of Janssen's Global Pharmaceuticals Sustainability Council.

Currently, Jane is a Non-Executive Director of the FTSE 100 companies, Johnson Matthey plc, BAE Systems plc, and is a member of the board of directors of TB Alliance, a not-for-profit organisation dedicated to the delivery of affordable tuberculosis drugs . Jane is a past Chair of the European Federation of Pharmaceutical Industries and Associations, past Chairwoman of the PhRMA Europe Committee and former member of the Corporate Advisory Board of the UK Government backed 'Your Life' campaign, aimed at encouraging more people to study STEM subjects.

Peter Presland, Interim Chairman of the Board of Redx commented : "We are pleased to welcome Jane as Chair of the Redx Board to lead the next stage of the Company growth. She brings a wealth of pertinent global experience to the Company from her long and varied career at Johnson & Johnson, her other board positions and as a fervent champion of sustainability and diversity across business. We look forward to drawing on these insights. It is a very exciting time for Redx, as we enter into Phase 2 clinical development with RXC004 as a potential treatment for Wnt-ligand driven cancers and continue to progress our Phase 1 study with RXC007 as a potential treatment for fibrotic diseases, including idiopathic pulmonary fibrosis."

Dr Jane Griffiths commented: "I am delighted to be joining Redx at an exciting time as its programmes continue to make progress in the clinic and its research scientists look to further expand the pipeline with differentiated assets. I look forward to working closely with the Board and the management team during this next stage of growth."

Following Dr Griffiths' appointment, the board will be comprised of seven directors, four of whom including the Chair are Independent Non-Executive Directors (Dr Jane Griffiths, Mr Peter Presland, Dr Bernard Kirschbaum and Sarah Gordon Wild), two shareholder representative Non-Executive Directors (Natalie Berner and Dr Thomas Burt) and Lisa Anson as Chief Executive Officer.

Additional information:

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Jane Veronica Griffiths, aged 65, holds or has previously held the following directorships:

 
 C urrent directorships and/or         Former directorships and/or 
  partnerships                          partnerships (within the last 
                                        five years): 
 Johnson Matthey PLC                   None 
  BAE Systems PLC 
  The TB Alliance 
  The White Ribbon Alliance 
  Voza Developments Kinnerton 
  Limited 
  Voza Developments Passmore Limited 
                                      ------------------------------- 
 

She does not currently hold any ordinary shares in the Company.

For further information, please contact:

 
Redx Pharma Plc                              T: +44 (0)1625 469 
                                                            918 
UK Headquarters 
 Peter Presland, Interim Chairman 
 Lisa Anson, Chief Executive Officer 
 Karl Hård, Head of Investor Relations 
 
 US Office 
 Peter Collum, Chief Financial Officer 
 
SPARK Advisory Partners Limited (Nominated    T: +44 (0)20 3368 
 Advisor)                                                  3550 
Matt Davis/Adam Dawes 
 
WG Partners LLP (Joint Broker)                T: +44 (0)20 3705 
                                                           9330 
Claes Spång/David Wilson 
 
Panmure Gordon (UK) Limited (Joint Broker)    T: +44 (0)20 7886 
                                                           2500 
Rupert Dearden/Freddy Crossley/Emma Earl 
 
FTI Consulting                                T: +44 (0)20 3727 
                                                           1000 
Simon Conway/Ciara Martin 
 

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx's lead oncology asset, the Porcupine inhibitor RXC004, is expected to commence a Phase 2 programme in the second half of 2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical study in June 2021. Initial encouraging results were reported in October 2021 and further results are expected in the first half of 2022.

The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, with five proprietary or partnered assets in late pre-clinical or clinical development. One of those assets, a BTK inhibitor - pirtobrutinib/LOXO-305 - was sold to Loxo Oncology (now Eli Lilly) and is currently in several Phase 3 clinical studies, including chronic lymphocytic leukaemia. In addition, Redx has forged pre-clinical asset partnerships with other blue chip companies including AstraZeneca and Jazz Pharmaceuticals.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAEANEFDSAFFFA

(END) Dow Jones Newswires

November 01, 2021 03:00 ET (07:00 GMT)

Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024